In the United States, more than 7,000 rare diseases collectively affect more than 25 million Americans.

Orphan diseases, including rare diseases, are neglected conditions whose treatments are often not considered profitable due to their cost to develop and limited patient population.

The Orphan Drug Act of 1983 provides critical incentives and resources for those developing medicines for rare diseases. Under this legislation, a rare or “orphan” disease became defined as a disease or disorder affecting fewer than 200,000 people in the U.S. Since the passage of the Orphan Drug Act, the pace of development of new medicines for rare diseases has increased significantly. Since 1983, more than 350 new medicines to treat rare diseases have been approved FDA. Even with this progress, we still face a huge challenge. Almost 95% of all patients afflicted with a rare disease still have no treatment options. Despite nearly thirty years of effort by academia, government agencies, rare disease patients groups, the medical community and the private sector, we still have only about 420 approved therapies.

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from Youtube
Consent to display content from Vimeo
Google Maps
Consent to display content from Google